Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ganlong is a proprietary oral capsule developed and marketed in China for the treatment of chronic hepatitis B. Its principal active ingredient is an extract from Periplaneta americana (American cockroach), a substance used in traditional Chinese medicine. Preclinical studies have shown that Ganlong inhibits hepatitis B virus DNA replication, reduces liver enzyme levels (ALT), improves HBeAg seroconversion rates, and protects against both acute and chronic liver injury in animal models. It also demonstrates anti-fibrotic effects by inhibiting hepatic stellate cell activity and modulating metabolic pathways involved in liver fibrosis. The precise molecular mechanism remains incompletely characterized but includes immunomodulatory and hepatoprotective actions[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ganlong.